Filing Analysis
Instil Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected two Class II directors and ratified the appointment of RSM US LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on June 11, 2026.
- Quorum achieved with 5,757,919 shares represented (approx. 84.9% of 6,781,976 outstanding shares).
- George Matcham and Neil Gibson were elected as Class II directors until the 2029 Annual Meeting.
- RSM US LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Instil Bio, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a general corporate update. The information was disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes a press release (Exhibit 99.1) dated May 15, 2026.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Instil Bio, Inc. dismissed Deloitte & Touche LLP as its independent registered public accounting firm and appointed RSM US LLP, effective April 1, 2026. The company reported no disagreements or reportable events regarding accounting principles or disclosures during the fiscal years 2024 and 2025.
🚩 Red Flags
- Down-tiering of auditor from a 'Big Four' firm (Deloitte) to a mid-tier firm (RSM), which can sometimes precede changes in financial reporting complexity or cost-cutting measures.
📋 Key Facts
- Dismissed Deloitte & Touche LLP as the independent auditor effective April 1, 2026.
- Appointed RSM US LLP as the new independent auditor for the fiscal year ending December 31, 2026.
- Deloitte's audit reports for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions or qualifications.
- No disagreements were reported with Deloitte on any matters of accounting principles, practices, or financial statement disclosures.
- The filing includes a letter from Deloitte (Exhibit 16.1) agreeing with the company's statements.
Instil Bio, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Financial results cover the fourth quarter and the full fiscal year ended December 31, 2025.
- The report was filed on March 27, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes a press release (Exhibit 99.1) containing the detailed corporate update.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.